Clinical Pharmacology of Ixazomib: The First Oral Proteasome Inhibitor

Ixazomib, the first oral proteasome inhibitor, is approved in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma (MM) who have received at least one prior therapy. Ixazomib is a selective, potent, and reversible inhibitor of the 20S proteasome, and pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Gupta, Neeraj, Hanley, Michael J., Xia, Cindy, Labotka, Richard, Harvey, R. Donald, Venkatakrishnan, Karthik
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2018
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6397141/
https://www.ncbi.nlm.nih.gov/pubmed/30117017
http://dx.doi.org/10.1007/s40262-018-0702-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6397141/
https://www.ncbi.nlm.nih.gov/pubmed/30117017
http://dx.doi.org/10.1007/s40262-018-0702-1

Ejemplares similares